Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses
Aleksandra K. Kurowska, Azari BantaniD, Raghad ShuwaikaniD, Nahia Gómez-EcharteiD, Itziar CenzanoiD, Paula Aguirre‐RuiziD, Estíbaliz MirandaiD, Leire Gárate, Amaia Vilas‐ZornozaiD, Patxi San-Martin, Marta LarráyoziD, Beñat AricetaiD, Ane Amundarain, Daniel Soto Ortiz, Markos Tsitsianopoulos, Argyris PapantonisiD, María José CalasanziD, José Ignacio Martín-SuberoiD, Vincenzo LaganiiD, Jesper N. TegneriD, Jose Angel Martinez-ClimentiD, Mikel HernáeziD, Nuria Planell, Xabier AgirreiD, Felipe PrósperiD, David Gómez-CabreroiD
Abstract
AbstractMultiple myeloma (MM) evolves from asymptomatic precursor conditions through progressive genetic and epigenetic remodeling, yet the regulatory mechanisms driving the development toward more active stages of the disease remain poorly understood. Here, we integrated bulk-based paired chromatin accessibility and activation, and transcriptomic profiling across disease stages to map regulatory remodeling during myeloma development. We identified a progressive increase in chromatin accessibility; furthermore, this epigenetic reconfiguration is accompanied by a stage-dependent shift from promoter-centered regulation in precursor states toward enhancer-dominated transcriptional control in active MM. Motif enrichment and regulatory network analyses identified both established and previously underappreciated transcription factors (TFs), including members of the IRF, MEF2, and FOX families, associated with disease-stage-specific transcriptional programs. Among these, MEF2D and FOXK2 emerged as candidate regulators of pathways involved in cell survival and chemotaxis. Functional perturbation demonstrated that MEF2D depletion markedly impaired MM cell viability, whereas inhibition of either MEF2D or FOXK2 reduced chemotactic migration. Together, these findings provide a stage-resolved framework of epigenetic and transcriptional remodeling across myeloma development, revealing regulatory programs established in precursor conditions and progressively reinforced during disease evolution, while identifying candidate transcriptional dependencies with potential biological and therapeutic relevance.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Over-accessible chromatin links myeloma initiating genetic events to oncogenic transcriptomes and aberrant transcription factor regulatory networks
J. Alvarez-Benayas, A. Katsarou, … A. Karadimitris·bioRxiv·Jun 11, 2020
- Novel mechanism of MYC deregulation in Multiple Myeloma
M. Rahmat, K. Clement, … I. M. Ghobrial·bioRxiv·May 19, 2023
- Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma
R. Ordonez, M. Kulis, … J. I. Martin-Subero·bioRxiv·Aug 20, 2019
- Aberrant non-canonical NF-kappaB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma
D. A. Ang, J.-M. Carter, … Y. Li·bioRxiv·Jan 9, 2024
- Methylation variability and LINE-1 activation in multiple myeloma
Qianhui Wan, Amy Leung, … Dustin E. Schones·bioRxiv·Jul 22, 2025
- DNA hydroxymethylation reveals transcription regulation networks and prognostic signatures in multiple myeloma
J.-B. Alberge, F. Magrangeas, … A. A. Serandour·bioRxiv·Oct 16, 2019